loading
Lexeo Therapeutics Inc stock is traded at $3.96, with a volume of 77,251. It is down -1.01% in the last 24 hours and up +0.26% over the past month. Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
See More
Previous Close:
$3.96
Open:
$3.95
24h Volume:
77,251
Relative Volume:
0.11
Market Cap:
$130.13M
Revenue:
-
Net Income/Loss:
$-86.60M
P/E Ratio:
-1.3981
EPS:
-2.8324
Net Cash Flow:
$-67.37M
1W Performance:
-4.85%
1M Performance:
+0.26%
6M Performance:
-20.00%
1Y Performance:
-66.03%
1-Day Range:
Value
$3.86
$3.97
1-Week Range:
Value
$3.86
$4.40
52-Week Range:
Value
$1.45
$13.63

Lexeo Therapeutics Inc Stock (LXEO) Company Profile

Name
Name
Lexeo Therapeutics Inc
Name
Phone
(212) 547-9879
Name
Address
345 PARK AVENUE SOUTH, NEW YORK
Name
Employee
75
Name
Twitter
Name
Next Earnings Date
2025-03-24
Name
Latest SEC Filings
Name
LXEO's Discussions on Twitter

Compare LXEO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LXEO
Lexeo Therapeutics Inc
3.92 239.68M 0 -86.60M -67.37M -2.8324
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.99 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
556.62 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.96 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.29 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
293.25 27.29B 3.81B -644.79M -669.77M -6.24

Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-13-24 Initiated Robert W. Baird Outperform
Jun-06-24 Initiated H.C. Wainwright Buy
Nov-28-23 Initiated Chardan Capital Markets Buy
Nov-28-23 Initiated JP Morgan Overweight
Nov-28-23 Initiated Leerink Partners Outperform
Nov-28-23 Initiated RBC Capital Mkts Outperform
Nov-28-23 Initiated Stifel Buy
View All

Lexeo Therapeutics Inc Stock (LXEO) Latest News

pulisher
04:19 AM

Is Lexeo Therapeutics Inc. a good long term investmentRapid wealth accumulation - jammulinksnews.com

04:19 AM
pulisher
Jul 20, 2025

Lexeo Therapeutics Inc. Stock Analysis and ForecastExceptional return forecasts - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Lexeo Therapeutics Inc. stockFree Stock Index Interpretation - Autocar Professional

Jul 20, 2025
pulisher
Jul 20, 2025

What drives Lexeo Therapeutics Inc. stock priceUnprecedented growth rates - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

Will Lexeo Therapeutics Inc. stock split in the near futureSafe and Smart Investment Picks - beatles.ru

Jul 19, 2025
pulisher
Jul 18, 2025

Lexeo Therapeutics (NASDAQ:LXEO) & Organogenesis (NASDAQ:ORGO) Head to Head Analysis - Defense World

Jul 18, 2025
pulisher
Jul 18, 2025

What analysts say about Lexeo Therapeutics Inc. stock outlookFree Investment Portfolio Suggestions - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

How high can Lexeo Therapeutics Inc. stock price go in 2025Safe and Smart Investment Picks - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

What makes Lexeo Therapeutics Inc. stock price move sharplyFree Access to Community with 300% Return - beatles.ru

Jul 17, 2025
pulisher
Jul 15, 2025

Why Lexeo Therapeutics Inc. stock attracts strong analyst attentionFree Expert-Led Investment Training - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Lexeo Therapeutics Inc. stock performs during market volatilityCarefully Curated High Return Stocks - Newser

Jul 15, 2025
pulisher
Jul 11, 2025

Lexeo Therapeutics soars 96% following March Fair Value signal By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Lexeo Therapeutics soars 96% following March Fair Value signal - Investing.com

Jul 11, 2025
pulisher
Jul 07, 2025

Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

Stifel reiterates Buy rating on Lexeo Therapeutics stock at $21 price target By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 07, 2025

Lexeo Therapeutics stock rises after FDA breakthrough designation By Investing.com - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

Lexeo Therapeutics Secures FDA Breakthrough Therapy Designation for LX2006, Shares Rise 8% in Pre-market Trade. - AInvest

Jul 07, 2025
pulisher
Jul 07, 2025

Lexeo Therapeutics announces FDA Breakthrough Therapy Designation for LX2006 - TipRanks

Jul 07, 2025
pulisher
Jul 07, 2025

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia Treatment - Nasdaq

Jul 07, 2025
pulisher
Jul 07, 2025

FDA grants breakthrough therapy designation to Lexeo’s FA treatment - Investing.com

Jul 07, 2025
pulisher
Jul 07, 2025

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - GlobeNewswire

Jul 07, 2025
pulisher
Jul 07, 2025

FDA Breakthrough: Lexeo's Gene Therapy Shows Promise in Fatal Rare Disease Treatment - Stock Titan

Jul 07, 2025
pulisher
Jul 07, 2025

FDA grants breakthrough therapy designation to Lexeo’s FA treatment By Investing.com - Investing.com South Africa

Jul 07, 2025
pulisher
Jul 01, 2025

LXEO files 41.6M-share prospectus; $80M raise backs accelerated LX2006 plan | ATNFW SEC FilingForm 8-K - Stock Titan

Jul 01, 2025
pulisher
Jul 01, 2025

LXEO files 41.6M-share prospectus; $80M raise backs accelerated LX2006 plan - Stock Titan

Jul 01, 2025
pulisher
Jun 30, 2025

Lexeo Therapeutics stockholders elect directors and ratify auditor at annual meeting - Investing.com

Jun 30, 2025
pulisher
Jun 30, 2025

Lexeo Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks

Jun 30, 2025
pulisher
Jun 29, 2025

Lexeo Therapeutics, Inc.(NasdaqGM: LXEO) dropped from Russell 2000 Growth Index - MarketScreener

Jun 29, 2025
pulisher
Jun 27, 2025

Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases - Pharmafile

Jun 27, 2025
pulisher
Jun 24, 2025

Lexeo Therapeutics Partners with PXV Funds, venBio on New Cardiac RNA Therapeutics Venture - MarketScreener

Jun 24, 2025
pulisher
Jun 16, 2025

Bank of America Corp DE Trims Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

Jun 16, 2025
pulisher
Jun 14, 2025

Lexeo Therapeutics files to sell 41.63M shares of common stock for holders - MSN

Jun 14, 2025
pulisher
Jun 14, 2025

Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Lexeo Therapeutics Registers Share Offering on Behalf of Selling Stockholders - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Lexeo Therapeutics (LXEO) Proposes Sale of 41.63 Million Shares | LXEO Stock News - GuruFocus

Jun 13, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stake Lifted by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by Millennium Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 04, 2025

Deutsche Bank AG Buys 8,378 Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - Defense World

Jun 04, 2025

Lexeo Therapeutics Inc Stock (LXEO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lexeo Therapeutics Inc Stock (LXEO) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Adler Eric
Chief Medical Officer
May 16 '25
Sale
2.77
585
1,623
67,681
Robertson Jenny
Chief Legal Officer
May 16 '25
Sale
2.77
521
1,445
63,098
See Tai Sandi
Chief Development Officer
May 16 '25
Sale
2.77
367
1,018
59,242
$21.65
price down icon 0.28%
$35.66
price down icon 0.06%
$103.64
price up icon 0.83%
$26.24
price down icon 0.65%
$109.96
price up icon 0.27%
biotechnology ONC
$291.99
price up icon 0.02%
Cap:     |  Volume (24h):